Postdoctoral Associate
Duke University’
I am a Postdoctoral Associate in the Department of Medicine at Duke University, where my research focuses on overcoming therapy resistance in prostate cancer. My work combines molecular biology, biochemistry, and translational models to develop novel targeted and combination therapies, identify predictive biomarkers, and uncover the molecular mechanisms that drive drug resistance. With more than a decade of experience in cancer biology, I am deeply committed to advancing discoveries that can ultimately improve patient outcomes.
I began my academic journey in India, earning my B.Sc. in Biotechnology from the University of Burdwan, followed by an M.Sc. in Medical Biotechnology from Jadavpur University. I completed my Ph.D. in Biochemistry at the University of Calcutta in 2021, where I studied novel anti-cancer agents derived from natural sources and their chemically modified analogs. This work led to the identification of compounds with strong anti-cancer potential and minimal toxicity, published in ACS Pharmacology & Translational Science and RSC Advances.
After my Ph.D., I joined the University of North Carolina at Chapel Hill as a Postdoctoral Research Associate. There, I investigated the molecular and physiological mechanisms that link pancreatic cancer progression with thrombosis, focusing on fibrinolytic pathways. This research advanced understanding of the pro-thrombotic environment in pancreatic ductal adenocarcinoma, resulting in publications in Molecular Oncology and an invited talk at the Gordon Research Conference.
Since 2023, I have been continuing my postdoctoral research at Duke University, where I focus on defining therapeutic vulnerabilities in drug-resistant prostate cancer. My recent work has been published in Science Advances and Cellular and Molecular Life Sciences, and I was selected to present at the AACR Annual Meeting 2025. Looking ahead, my goal is to illuminate new therapeutic strategies for therapy-resistant cancers and contribute to improving survival and quality of life for patients.
